Skip to main content
. 2022 Jan 18;11(3):472. doi: 10.3390/jcm11030472

Table 3.

Demographic, treatment, and outcome data.

Control Group Hip Dislocation
Male sex % (n) 71.5% (121,053) 79.5% (1087)
Mean age (SD), years 49 (22) 43 (19)
ISS: mean (SD), points 21.7 (12) 22.4 (12)
New ISS: mean (SD), points 26.2 (14) 26.7 (13)
Level 1 center admission % (n) 66.8% (113,218) 66.5% (912)
Level 2 center admission % (n) 24.9% (42,289) 26.6% (365)
Level 3 center admission % (n) 8.3% (14,056) 6.9% (94)
ICU treatment % (n) 88.2% (149,471) 93.1% (1277)
ICU LOS days † 7.5/3 (11) 9.1/4 (13)
Ventilator, mean days (SD) 3.7 (9) 4.6 (9)
Hospital LOS: days † 20/14 (21) 27/22 (24)
Delayed identification β NA 1.1% (7)
Surgery for dislocated hip % (n) NA 70.9% (518)
Discharged fully recovered % (n) 56.3% (92,186) 48.2% (639)
Discharged with minor impairment % (n) 23.6% (38,560) 33.5% (444)
Discharged with severe impairment % (n) 7.7% (12,540) 9.0% (119)
Discharged with PVS 1.4% (2229) 1.2% (16)
Predicted mortality (RISC II) 10.8% 8.7%
Observed mortality % (n) 10.7% (18,216) 7.8% (107)
Mean treatment costs (Euro) 18,600 24,659

LOS = length of stay; ICU = intensive care unit; NA = not applicable; HD = Hip dislocation, RISC II = Revised Injury Severity Score II; PVS = persistent vegetative state; (†) mean/median (SD); (β) Hip dislocation diagnosed at ICU or later; available for cases with standard documentation only.